Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Gout Flares (β-RELIEVED-II)
NCT01080131Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of canakinumab in gout, sponsored by Novartis. Started Mar 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
gout
Beyond the preview
Go deeper on NCT01080131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01080131.